Oncolytics Biotech Inc. (ONCY)

[onco_investor]

Reovirus Activates Human Innate Immune Cell Killing of Colorectal Metastases in Vitro

Metastatic Colorectal Trial REO-013

Scheduled to be published at the 9th World Congress of the International Hepato-Pancreato- Biliary Association, to be presented by Robert Adair (part of Alan Melcher's team in Leeds UK) on Mon April 19, 2010. at 14:30 local time in Buenos Aires

http://www.ihpba-ba2010.com/scientific-programme/free-papers-sessions


REO-013 Details from Oncolytics website

http://www.oncolyticsbiotech.com/clinicaltrial_REO_013.html

"The trial (REO 013) is an open-label, non-randomized, single centre study of REOLYSIN® given intravenously to patients for five consecutive days in advance of their scheduled operations to remove colorectal cancer deposits metastatic to the liver. Patients will comprise two groups receiving REOLYSIN®, either at an early (21 to 10 days) or late time point (less than 10 days) before surgical resection. After surgery, the tumour and surrounding liver tissue will be assessed for viral status and anti-tumour effects."


Stay Tuned... details Monday! Thanks to RJC for uncovering this one.